Preliminary Study of Two Antiviral Agents for Hepatitis C Genotype 1
In 21 patients with hepatitis C virus genotype 1 infection who had had no response to prior treatment, sustained virologic responses were achieved in 4 of 11 who were treated with two antiviral agents alone and in 9 of 10 who were treated with the antiviral agents plus peginterferon and ribavirin. A...
Gespeichert in:
| Veröffentlicht in: | The New England journal of medicine 2012-01, Vol.366 (3), p.216-224 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 224 |
|---|---|
| container_issue | 3 |
| container_start_page | 216 |
| container_title | The New England journal of medicine |
| container_volume | 366 |
| creator | Lok, Anna S Gardiner, David F Lawitz, Eric Martorell, Claudia Everson, Gregory T Ghalib, Reem Reindollar, Robert Rustgi, Vinod McPhee, Fiona Wind-Rotolo, Megan Persson, Anna Zhu, Kurt Dimitrova, Dessislava I Eley, Timothy Guo, Tong Grasela, Dennis M Pasquinelli, Claudio |
| description | In 21 patients with hepatitis C virus genotype 1 infection who had had no response to prior treatment, sustained virologic responses were achieved in 4 of 11 who were treated with two antiviral agents alone and in 9 of 10 who were treated with the antiviral agents plus peginterferon and ribavirin.
Approximately 180 million people worldwide are infected with hepatitis C virus (HCV), including 4.1 million in the United States.
1
,
2
HCV infection is the most common cause of chronic liver disease in the United States and a leading cause of cirrhosis and hepatocellular carcinoma globally.
3
,
4
HCV is classified into six major genotypes; genotype 1 is predominant in the United States and is the most difficult to treat.
5
,
6
Treatment of HCV genotype 1 infection with peginterferon alfa and ribavirin for 48 weeks results in 24-week sustained virologic response (undetectable HCV RNA 24 weeks after the end of therapy) in . . . |
| doi_str_mv | 10.1056/NEJMoa1104430 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_917157871</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2565402221</sourcerecordid><originalsourceid>FETCH-LOGICAL-c484t-c93ac838f1ba8283e624fb0ecdcbf2ced577b471ee076e416772a9fc347c94a3</originalsourceid><addsrcrecordid>eNp10E1PGzEQBmALgUigPXKtLCTEacHf3j1GISVFoa3U3FdeZ1w52l2n9m6r_HtckYKKxFzm8uid0YvQBSU3lEh1-3Xx8BgMpUQITo7QlErOCyGIOkZTQlhZCF3xCTpLaUvyUFGdogljTKqSyCm6-x6h9Z3vTdzjH8O42ePg8PpPwLN-8L99NC2e_YR-SNiFiJewM4MffMJzfA99GPY7wPQDOnGmTfDxsM_R-vNiPV8Wq2_3X-azVWFFKYbCVtzYkpeONqZkJQfFhGsI2I1tHLOwkVo3QlMAohUIqrRmpnKWC20rYfg5un6O3cXwa4Q01J1PFtrW9BDGVFdUU6lLTbO8fCO3YYx9_i0jlZ1kLKPiGdkYUorg6l30Xe6hpqT-2239X7fZfzqEjk0Hmxf9r8wMrg7AJGtaF01vfXp1UmglpXp1XZfqHrbdOwefAAl3iyU</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>916917522</pqid></control><display><type>article</type><title>Preliminary Study of Two Antiviral Agents for Hepatitis C Genotype 1</title><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>New England Journal of Medicine</source><creator>Lok, Anna S ; Gardiner, David F ; Lawitz, Eric ; Martorell, Claudia ; Everson, Gregory T ; Ghalib, Reem ; Reindollar, Robert ; Rustgi, Vinod ; McPhee, Fiona ; Wind-Rotolo, Megan ; Persson, Anna ; Zhu, Kurt ; Dimitrova, Dessislava I ; Eley, Timothy ; Guo, Tong ; Grasela, Dennis M ; Pasquinelli, Claudio</creator><creatorcontrib>Lok, Anna S ; Gardiner, David F ; Lawitz, Eric ; Martorell, Claudia ; Everson, Gregory T ; Ghalib, Reem ; Reindollar, Robert ; Rustgi, Vinod ; McPhee, Fiona ; Wind-Rotolo, Megan ; Persson, Anna ; Zhu, Kurt ; Dimitrova, Dessislava I ; Eley, Timothy ; Guo, Tong ; Grasela, Dennis M ; Pasquinelli, Claudio</creatorcontrib><description>In 21 patients with hepatitis C virus genotype 1 infection who had had no response to prior treatment, sustained virologic responses were achieved in 4 of 11 who were treated with two antiviral agents alone and in 9 of 10 who were treated with the antiviral agents plus peginterferon and ribavirin.
Approximately 180 million people worldwide are infected with hepatitis C virus (HCV), including 4.1 million in the United States.
1
,
2
HCV infection is the most common cause of chronic liver disease in the United States and a leading cause of cirrhosis and hepatocellular carcinoma globally.
3
,
4
HCV is classified into six major genotypes; genotype 1 is predominant in the United States and is the most difficult to treat.
5
,
6
Treatment of HCV genotype 1 infection with peginterferon alfa and ribavirin for 48 weeks results in 24-week sustained virologic response (undetectable HCV RNA 24 weeks after the end of therapy) in . . .</description><identifier>ISSN: 0028-4793</identifier><identifier>EISSN: 1533-4406</identifier><identifier>DOI: 10.1056/NEJMoa1104430</identifier><identifier>PMID: 22256805</identifier><identifier>CODEN: NEJMAG</identifier><language>eng</language><publisher>Waltham, MA: Massachusetts Medical Society</publisher><subject>Adult ; Alanine ; Alanine transaminase ; Antibiotics. Antiinfectious agents. Antiparasitic agents ; Antiviral agents ; Antiviral Agents - adverse effects ; Antiviral Agents - therapeutic use ; Antiviral drugs ; Biological and medical sciences ; Chronic infection ; Diarrhea ; Drug Resistance, Viral ; Drug therapy ; Drug Therapy, Combination ; Female ; General aspects ; Genotype ; Genotype & phenotype ; Genotypes ; Hepacivirus - genetics ; Hepatitis ; Hepatitis C ; Hepatitis C, Chronic - drug therapy ; Human viral diseases ; Humans ; Imidazoles - adverse effects ; Imidazoles - therapeutic use ; Infectious diseases ; Interferon-alpha - adverse effects ; Interferon-alpha - therapeutic use ; Male ; Medical sciences ; Middle Aged ; Patients ; Pharmacology. Drug treatments ; Polyethylene Glycols - adverse effects ; Polyethylene Glycols - therapeutic use ; Proteinase inhibitors ; Recombinant Proteins - adverse effects ; Recombinant Proteins - therapeutic use ; Recurrence ; Ribavirin ; Ribavirin - adverse effects ; Ribavirin - therapeutic use ; Ribonucleic acid ; RNA ; RNA, Viral - blood ; Viral diseases ; Viral hepatitis</subject><ispartof>The New England journal of medicine, 2012-01, Vol.366 (3), p.216-224</ispartof><rights>Copyright © 2012 Massachusetts Medical Society. All rights reserved.</rights><rights>2015 INIST-CNRS</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c484t-c93ac838f1ba8283e624fb0ecdcbf2ced577b471ee076e416772a9fc347c94a3</citedby><cites>FETCH-LOGICAL-c484t-c93ac838f1ba8283e624fb0ecdcbf2ced577b471ee076e416772a9fc347c94a3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.nejm.org/doi/pdf/10.1056/NEJMoa1104430$$EPDF$$P50$$Gmms$$H</linktopdf><linktohtml>$$Uhttps://www.nejm.org/doi/full/10.1056/NEJMoa1104430$$EHTML$$P50$$Gmms$$H</linktohtml><link.rule.ids>314,776,780,2746,2747,26080,27901,27902,52357,54039</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=25476556$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/22256805$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Lok, Anna S</creatorcontrib><creatorcontrib>Gardiner, David F</creatorcontrib><creatorcontrib>Lawitz, Eric</creatorcontrib><creatorcontrib>Martorell, Claudia</creatorcontrib><creatorcontrib>Everson, Gregory T</creatorcontrib><creatorcontrib>Ghalib, Reem</creatorcontrib><creatorcontrib>Reindollar, Robert</creatorcontrib><creatorcontrib>Rustgi, Vinod</creatorcontrib><creatorcontrib>McPhee, Fiona</creatorcontrib><creatorcontrib>Wind-Rotolo, Megan</creatorcontrib><creatorcontrib>Persson, Anna</creatorcontrib><creatorcontrib>Zhu, Kurt</creatorcontrib><creatorcontrib>Dimitrova, Dessislava I</creatorcontrib><creatorcontrib>Eley, Timothy</creatorcontrib><creatorcontrib>Guo, Tong</creatorcontrib><creatorcontrib>Grasela, Dennis M</creatorcontrib><creatorcontrib>Pasquinelli, Claudio</creatorcontrib><title>Preliminary Study of Two Antiviral Agents for Hepatitis C Genotype 1</title><title>The New England journal of medicine</title><addtitle>N Engl J Med</addtitle><description>In 21 patients with hepatitis C virus genotype 1 infection who had had no response to prior treatment, sustained virologic responses were achieved in 4 of 11 who were treated with two antiviral agents alone and in 9 of 10 who were treated with the antiviral agents plus peginterferon and ribavirin.
Approximately 180 million people worldwide are infected with hepatitis C virus (HCV), including 4.1 million in the United States.
1
,
2
HCV infection is the most common cause of chronic liver disease in the United States and a leading cause of cirrhosis and hepatocellular carcinoma globally.
3
,
4
HCV is classified into six major genotypes; genotype 1 is predominant in the United States and is the most difficult to treat.
5
,
6
Treatment of HCV genotype 1 infection with peginterferon alfa and ribavirin for 48 weeks results in 24-week sustained virologic response (undetectable HCV RNA 24 weeks after the end of therapy) in . . .</description><subject>Adult</subject><subject>Alanine</subject><subject>Alanine transaminase</subject><subject>Antibiotics. Antiinfectious agents. Antiparasitic agents</subject><subject>Antiviral agents</subject><subject>Antiviral Agents - adverse effects</subject><subject>Antiviral Agents - therapeutic use</subject><subject>Antiviral drugs</subject><subject>Biological and medical sciences</subject><subject>Chronic infection</subject><subject>Diarrhea</subject><subject>Drug Resistance, Viral</subject><subject>Drug therapy</subject><subject>Drug Therapy, Combination</subject><subject>Female</subject><subject>General aspects</subject><subject>Genotype</subject><subject>Genotype & phenotype</subject><subject>Genotypes</subject><subject>Hepacivirus - genetics</subject><subject>Hepatitis</subject><subject>Hepatitis C</subject><subject>Hepatitis C, Chronic - drug therapy</subject><subject>Human viral diseases</subject><subject>Humans</subject><subject>Imidazoles - adverse effects</subject><subject>Imidazoles - therapeutic use</subject><subject>Infectious diseases</subject><subject>Interferon-alpha - adverse effects</subject><subject>Interferon-alpha - therapeutic use</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Patients</subject><subject>Pharmacology. Drug treatments</subject><subject>Polyethylene Glycols - adverse effects</subject><subject>Polyethylene Glycols - therapeutic use</subject><subject>Proteinase inhibitors</subject><subject>Recombinant Proteins - adverse effects</subject><subject>Recombinant Proteins - therapeutic use</subject><subject>Recurrence</subject><subject>Ribavirin</subject><subject>Ribavirin - adverse effects</subject><subject>Ribavirin - therapeutic use</subject><subject>Ribonucleic acid</subject><subject>RNA</subject><subject>RNA, Viral - blood</subject><subject>Viral diseases</subject><subject>Viral hepatitis</subject><issn>0028-4793</issn><issn>1533-4406</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2012</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>BEC</sourceid><sourceid>BENPR</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNp10E1PGzEQBmALgUigPXKtLCTEacHf3j1GISVFoa3U3FdeZ1w52l2n9m6r_HtckYKKxFzm8uid0YvQBSU3lEh1-3Xx8BgMpUQITo7QlErOCyGIOkZTQlhZCF3xCTpLaUvyUFGdogljTKqSyCm6-x6h9Z3vTdzjH8O42ePg8PpPwLN-8L99NC2e_YR-SNiFiJewM4MffMJzfA99GPY7wPQDOnGmTfDxsM_R-vNiPV8Wq2_3X-azVWFFKYbCVtzYkpeONqZkJQfFhGsI2I1tHLOwkVo3QlMAohUIqrRmpnKWC20rYfg5un6O3cXwa4Q01J1PFtrW9BDGVFdUU6lLTbO8fCO3YYx9_i0jlZ1kLKPiGdkYUorg6l30Xe6hpqT-2239X7fZfzqEjk0Hmxf9r8wMrg7AJGtaF01vfXp1UmglpXp1XZfqHrbdOwefAAl3iyU</recordid><startdate>20120119</startdate><enddate>20120119</enddate><creator>Lok, Anna S</creator><creator>Gardiner, David F</creator><creator>Lawitz, Eric</creator><creator>Martorell, Claudia</creator><creator>Everson, Gregory T</creator><creator>Ghalib, Reem</creator><creator>Reindollar, Robert</creator><creator>Rustgi, Vinod</creator><creator>McPhee, Fiona</creator><creator>Wind-Rotolo, Megan</creator><creator>Persson, Anna</creator><creator>Zhu, Kurt</creator><creator>Dimitrova, Dessislava I</creator><creator>Eley, Timothy</creator><creator>Guo, Tong</creator><creator>Grasela, Dennis M</creator><creator>Pasquinelli, Claudio</creator><general>Massachusetts Medical Society</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>0TZ</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>8AO</scope><scope>8C1</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AN0</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BEC</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>HCIFZ</scope><scope>K0Y</scope><scope>LK8</scope><scope>M0R</scope><scope>M0T</scope><scope>M1P</scope><scope>M2M</scope><scope>M2O</scope><scope>M2P</scope><scope>M7P</scope><scope>MBDVC</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>PSYQQ</scope><scope>Q9U</scope><scope>7X8</scope></search><sort><creationdate>20120119</creationdate><title>Preliminary Study of Two Antiviral Agents for Hepatitis C Genotype 1</title><author>Lok, Anna S ; Gardiner, David F ; Lawitz, Eric ; Martorell, Claudia ; Everson, Gregory T ; Ghalib, Reem ; Reindollar, Robert ; Rustgi, Vinod ; McPhee, Fiona ; Wind-Rotolo, Megan ; Persson, Anna ; Zhu, Kurt ; Dimitrova, Dessislava I ; Eley, Timothy ; Guo, Tong ; Grasela, Dennis M ; Pasquinelli, Claudio</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c484t-c93ac838f1ba8283e624fb0ecdcbf2ced577b471ee076e416772a9fc347c94a3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2012</creationdate><topic>Adult</topic><topic>Alanine</topic><topic>Alanine transaminase</topic><topic>Antibiotics. Antiinfectious agents. Antiparasitic agents</topic><topic>Antiviral agents</topic><topic>Antiviral Agents - adverse effects</topic><topic>Antiviral Agents - therapeutic use</topic><topic>Antiviral drugs</topic><topic>Biological and medical sciences</topic><topic>Chronic infection</topic><topic>Diarrhea</topic><topic>Drug Resistance, Viral</topic><topic>Drug therapy</topic><topic>Drug Therapy, Combination</topic><topic>Female</topic><topic>General aspects</topic><topic>Genotype</topic><topic>Genotype & phenotype</topic><topic>Genotypes</topic><topic>Hepacivirus - genetics</topic><topic>Hepatitis</topic><topic>Hepatitis C</topic><topic>Hepatitis C, Chronic - drug therapy</topic><topic>Human viral diseases</topic><topic>Humans</topic><topic>Imidazoles - adverse effects</topic><topic>Imidazoles - therapeutic use</topic><topic>Infectious diseases</topic><topic>Interferon-alpha - adverse effects</topic><topic>Interferon-alpha - therapeutic use</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Patients</topic><topic>Pharmacology. Drug treatments</topic><topic>Polyethylene Glycols - adverse effects</topic><topic>Polyethylene Glycols - therapeutic use</topic><topic>Proteinase inhibitors</topic><topic>Recombinant Proteins - adverse effects</topic><topic>Recombinant Proteins - therapeutic use</topic><topic>Recurrence</topic><topic>Ribavirin</topic><topic>Ribavirin - adverse effects</topic><topic>Ribavirin - therapeutic use</topic><topic>Ribonucleic acid</topic><topic>RNA</topic><topic>RNA, Viral - blood</topic><topic>Viral diseases</topic><topic>Viral hepatitis</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Lok, Anna S</creatorcontrib><creatorcontrib>Gardiner, David F</creatorcontrib><creatorcontrib>Lawitz, Eric</creatorcontrib><creatorcontrib>Martorell, Claudia</creatorcontrib><creatorcontrib>Everson, Gregory T</creatorcontrib><creatorcontrib>Ghalib, Reem</creatorcontrib><creatorcontrib>Reindollar, Robert</creatorcontrib><creatorcontrib>Rustgi, Vinod</creatorcontrib><creatorcontrib>McPhee, Fiona</creatorcontrib><creatorcontrib>Wind-Rotolo, Megan</creatorcontrib><creatorcontrib>Persson, Anna</creatorcontrib><creatorcontrib>Zhu, Kurt</creatorcontrib><creatorcontrib>Dimitrova, Dessislava I</creatorcontrib><creatorcontrib>Eley, Timothy</creatorcontrib><creatorcontrib>Guo, Tong</creatorcontrib><creatorcontrib>Grasela, Dennis M</creatorcontrib><creatorcontrib>Pasquinelli, Claudio</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Pharma and Biotech Premium PRO</collection><collection>Nursing & Allied Health Database</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>British Nursing Database</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>eLibrary</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>SciTech Premium Collection</collection><collection>New England Journal of Medicine</collection><collection>ProQuest Biological Science Collection</collection><collection>Consumer Health Database</collection><collection>Healthcare Administration Database</collection><collection>Medical Database</collection><collection>ProQuest Psychology</collection><collection>Research Library</collection><collection>Science Database</collection><collection>Biological Science Database</collection><collection>Research Library (Corporate)</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest One Psychology</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><jtitle>The New England journal of medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Lok, Anna S</au><au>Gardiner, David F</au><au>Lawitz, Eric</au><au>Martorell, Claudia</au><au>Everson, Gregory T</au><au>Ghalib, Reem</au><au>Reindollar, Robert</au><au>Rustgi, Vinod</au><au>McPhee, Fiona</au><au>Wind-Rotolo, Megan</au><au>Persson, Anna</au><au>Zhu, Kurt</au><au>Dimitrova, Dessislava I</au><au>Eley, Timothy</au><au>Guo, Tong</au><au>Grasela, Dennis M</au><au>Pasquinelli, Claudio</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Preliminary Study of Two Antiviral Agents for Hepatitis C Genotype 1</atitle><jtitle>The New England journal of medicine</jtitle><addtitle>N Engl J Med</addtitle><date>2012-01-19</date><risdate>2012</risdate><volume>366</volume><issue>3</issue><spage>216</spage><epage>224</epage><pages>216-224</pages><issn>0028-4793</issn><eissn>1533-4406</eissn><coden>NEJMAG</coden><abstract>In 21 patients with hepatitis C virus genotype 1 infection who had had no response to prior treatment, sustained virologic responses were achieved in 4 of 11 who were treated with two antiviral agents alone and in 9 of 10 who were treated with the antiviral agents plus peginterferon and ribavirin.
Approximately 180 million people worldwide are infected with hepatitis C virus (HCV), including 4.1 million in the United States.
1
,
2
HCV infection is the most common cause of chronic liver disease in the United States and a leading cause of cirrhosis and hepatocellular carcinoma globally.
3
,
4
HCV is classified into six major genotypes; genotype 1 is predominant in the United States and is the most difficult to treat.
5
,
6
Treatment of HCV genotype 1 infection with peginterferon alfa and ribavirin for 48 weeks results in 24-week sustained virologic response (undetectable HCV RNA 24 weeks after the end of therapy) in . . .</abstract><cop>Waltham, MA</cop><pub>Massachusetts Medical Society</pub><pmid>22256805</pmid><doi>10.1056/NEJMoa1104430</doi><tpages>9</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0028-4793 |
| ispartof | The New England journal of medicine, 2012-01, Vol.366 (3), p.216-224 |
| issn | 0028-4793 1533-4406 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_917157871 |
| source | MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; New England Journal of Medicine |
| subjects | Adult Alanine Alanine transaminase Antibiotics. Antiinfectious agents. Antiparasitic agents Antiviral agents Antiviral Agents - adverse effects Antiviral Agents - therapeutic use Antiviral drugs Biological and medical sciences Chronic infection Diarrhea Drug Resistance, Viral Drug therapy Drug Therapy, Combination Female General aspects Genotype Genotype & phenotype Genotypes Hepacivirus - genetics Hepatitis Hepatitis C Hepatitis C, Chronic - drug therapy Human viral diseases Humans Imidazoles - adverse effects Imidazoles - therapeutic use Infectious diseases Interferon-alpha - adverse effects Interferon-alpha - therapeutic use Male Medical sciences Middle Aged Patients Pharmacology. Drug treatments Polyethylene Glycols - adverse effects Polyethylene Glycols - therapeutic use Proteinase inhibitors Recombinant Proteins - adverse effects Recombinant Proteins - therapeutic use Recurrence Ribavirin Ribavirin - adverse effects Ribavirin - therapeutic use Ribonucleic acid RNA RNA, Viral - blood Viral diseases Viral hepatitis |
| title | Preliminary Study of Two Antiviral Agents for Hepatitis C Genotype 1 |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-08T06%3A45%3A41IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Preliminary%20Study%20of%20Two%20Antiviral%20Agents%20for%20Hepatitis%20C%20Genotype%201&rft.jtitle=The%20New%20England%20journal%20of%20medicine&rft.au=Lok,%20Anna%20S&rft.date=2012-01-19&rft.volume=366&rft.issue=3&rft.spage=216&rft.epage=224&rft.pages=216-224&rft.issn=0028-4793&rft.eissn=1533-4406&rft.coden=NEJMAG&rft_id=info:doi/10.1056/NEJMoa1104430&rft_dat=%3Cproquest_cross%3E2565402221%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=916917522&rft_id=info:pmid/22256805&rfr_iscdi=true |